IT1319701B1 - Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina - Google Patents

Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina

Info

Publication number
IT1319701B1
IT1319701B1 IT1999MI002520A ITMI992520A IT1319701B1 IT 1319701 B1 IT1319701 B1 IT 1319701B1 IT 1999MI002520 A IT1999MI002520 A IT 1999MI002520A IT MI992520 A ITMI992520 A IT MI992520A IT 1319701 B1 IT1319701 B1 IT 1319701B1
Authority
IT
Italy
Prior art keywords
macrolide
polyenic
stabilizing
procedure
crystalline form
Prior art date
Application number
IT1999MI002520A
Other languages
English (en)
Italian (it)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1319701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ITMI992520A0 publication Critical patent/ITMI992520A0/it
Publication of ITMI992520A1 publication Critical patent/ITMI992520A1/it
Application granted granted Critical
Publication of IT1319701B1 publication Critical patent/IT1319701B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IT1999MI002520A 1998-12-07 1999-12-02 Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina IT1319701B1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (3)

Publication Number Publication Date
ITMI992520A0 ITMI992520A0 (it) 1999-12-02
ITMI992520A1 ITMI992520A1 (it) 2001-06-02
IT1319701B1 true IT1319701B1 (it) 2003-10-27

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI002520A IT1319701B1 (it) 1998-12-07 1999-12-02 Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina

Country Status (38)

Country Link
US (5) US6605613B2 (enExample)
EP (4) EP1743657A3 (enExample)
JP (3) JP3805625B2 (enExample)
KR (2) KR100695834B1 (enExample)
CN (2) CN1876657B (enExample)
AR (3) AR026102A1 (enExample)
AT (1) ATE365051T1 (enExample)
AU (1) AU759219B2 (enExample)
BE (1) BE1012869A3 (enExample)
BR (1) BR9915986A (enExample)
CA (3) CA2651609A1 (enExample)
CO (1) CO4980847A1 (enExample)
CY (1) CY1106870T1 (enExample)
CZ (2) CZ303006B6 (enExample)
DE (1) DE69936352T3 (enExample)
DK (1) DK1137439T4 (enExample)
ES (1) ES2288033T5 (enExample)
FR (1) FR2786771B1 (enExample)
GB (2) GB9826882D0 (enExample)
HK (1) HK1038889B (enExample)
HU (2) HU230174B1 (enExample)
ID (1) ID29250A (enExample)
IL (1) IL143092A0 (enExample)
IT (1) IT1319701B1 (enExample)
MY (2) MY127579A (enExample)
NO (2) NO332698B1 (enExample)
NZ (2) NZ511936A (enExample)
PE (1) PE20001333A1 (enExample)
PL (2) PL196627B1 (enExample)
PT (1) PT1137439E (enExample)
RU (1) RU2243769C2 (enExample)
SG (1) SG151072A1 (enExample)
SI (1) SI1137439T2 (enExample)
SK (2) SK286688B6 (enExample)
TR (2) TR200201428T2 (enExample)
TW (2) TWI270550B (enExample)
WO (1) WO2000033878A2 (enExample)
ZA (1) ZA200104360B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CN100338043C (zh) 2002-02-13 2007-09-19 特瓦药厂私人有限公司 从生物物质中提取大环内酯的方法
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE04758730T1 (de) 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
KR20060052874A (ko) 2003-07-24 2006-05-19 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 정제 방법
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US20070255197A1 (en) * 2003-12-10 2007-11-01 Acrux Dds Pty Ltd Method of Treatment for Undesired Effect Following Transdermal or Topical Drug Delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
CA2581169A1 (en) * 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
AU2006322030A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
EP2576590A1 (en) * 2010-06-07 2013-04-10 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
EP2717884A1 (en) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (enExample) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
AU2021242202B2 (en) * 2020-03-27 2024-01-11 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
KR100400620B1 (ko) * 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
SI1208847T1 (sl) * 1996-07-30 2007-06-30 Novartis Ag Farmacevtski sestavki za zdravljenje stanj zavračanja transplantatov in avtoimunskih ali vnetnih stanj
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
CA2279259A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
CO4980847A1 (es) 2000-11-27
EP1137439B1 (en) 2007-06-20
ES2288033T3 (es) 2007-12-16
HU230174B1 (hu) 2015-09-28
BE1012869A3 (fr) 2001-04-03
SG151072A1 (en) 2009-06-29
WO2000033878A2 (en) 2000-06-15
PT1137439E (pt) 2007-09-25
US7297703B2 (en) 2007-11-20
TW200540179A (en) 2005-12-16
US6852729B2 (en) 2005-02-08
JP2006111637A (ja) 2006-04-27
HK1038889B (en) 2008-01-25
DE69936352D1 (de) 2007-08-02
NO20012424D0 (no) 2001-05-16
US20030191148A1 (en) 2003-10-09
RU2243769C2 (ru) 2005-01-10
KR100695834B1 (ko) 2007-03-19
GB9826882D0 (en) 1999-01-27
MY127579A (en) 2006-12-29
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
AU759219B2 (en) 2003-04-10
US20080161334A1 (en) 2008-07-03
EP2269651A2 (en) 2011-01-05
HU228939B1 (en) 2013-07-29
CZ303006B6 (cs) 2012-02-22
CN1261163C (zh) 2006-06-28
ITMI992520A1 (it) 2001-06-02
MY120594A (en) 2005-11-30
ZA200104360B (en) 2002-01-16
DE69936352T2 (de) 2008-02-14
SK287325B6 (sk) 2010-07-07
FR2786771B1 (fr) 2002-12-27
JP5043308B2 (ja) 2012-10-10
DE69936352T3 (de) 2012-05-03
DK1137439T4 (da) 2012-03-19
CZ20012001A3 (cs) 2001-09-12
CA2651609A1 (en) 2000-06-15
SK286688B6 (sk) 2009-03-05
CN1876657A (zh) 2006-12-13
WO2000033878A3 (en) 2000-11-02
US20050107418A1 (en) 2005-05-19
HK1038889A1 (en) 2002-04-04
CA2351580C (en) 2012-03-20
EP1137439B2 (en) 2011-11-23
SI1137439T2 (sl) 2012-05-31
US6605613B2 (en) 2003-08-12
CA2732620A1 (en) 2000-06-15
AR048073A2 (es) 2006-03-29
ITMI992520A0 (it) 1999-12-02
TWI248938B (en) 2006-02-11
NZ527781A (en) 2004-11-26
US20090270441A1 (en) 2009-10-29
EP1743657A2 (en) 2007-01-17
KR20010101128A (ko) 2001-11-14
KR20060096477A (ko) 2006-09-11
SI1137439T1 (sl) 2008-06-30
CA2351580A1 (en) 2000-06-15
PE20001333A1 (es) 2000-12-12
PL196627B1 (pl) 2008-01-31
HUP0104489A3 (en) 2004-05-28
US7572804B2 (en) 2009-08-11
EP1137439A2 (en) 2001-10-04
ID29250A (id) 2001-08-16
FR2786771A1 (fr) 2000-06-09
NO20012424L (no) 2001-05-16
PL208854B1 (pl) 2011-06-30
CA2732620C (en) 2013-08-06
AR026102A1 (es) 2003-01-29
SK7662001A3 (en) 2001-12-03
CN1876657B (zh) 2013-01-09
NO20121113L (no) 2001-05-16
NO332698B1 (no) 2012-12-10
ATE365051T1 (de) 2007-07-15
EP2279751A3 (en) 2011-02-16
JP2005200429A (ja) 2005-07-28
CZ302210B6 (cs) 2010-12-22
CN1374872A (zh) 2002-10-16
ES2288033T5 (es) 2012-04-10
JP2002531527A (ja) 2002-09-24
US7741338B2 (en) 2010-06-22
NZ511936A (en) 2003-10-31
NO334612B1 (no) 2014-04-22
JP5165199B2 (ja) 2013-03-21
TR200201428T2 (tr) 2002-12-23
GB9904934D0 (en) 1999-04-28
PL348333A1 (en) 2002-05-20
HUP0104489A2 (hu) 2002-03-28
IL143092A0 (en) 2002-04-21
AU1657300A (en) 2000-06-26
AR054444A2 (es) 2007-06-27
TR200101416T2 (tr) 2002-01-21
TWI270550B (en) 2007-01-11
EP2269651A3 (en) 2011-03-09
BR9915986A (pt) 2001-09-04
US20020032213A1 (en) 2002-03-14
EP2279751A2 (en) 2011-02-02
EP1743657A3 (en) 2007-03-28
JP3805625B2 (ja) 2006-08-02

Similar Documents

Publication Publication Date Title
IT1319701B1 (it) Procedimento per stabilizzare un macrolide polienicoed ed unparticolare macrolide ottenuto in forma cristallina
EP1221179A4 (en) STRONG TEXTURED ATOMIC EDGES AND POINTS
GB2339197B (en) Crystalline trehalose dihydrate
EP1312281A4 (en) METHOD AND DEVICE FOR MANUFACTURING A BRUSH
ATE227937T1 (de) Geformte eingefrorene konfektstange
IS5528A (is) Ný makrólíð
DE69838651D1 (de) Erythromycinderivate
EP1090566A4 (en) TOOTHBRUSH AND MANUFACTURING METHOD
FI19992112L (fi) Synkronointimenetelmä ja -järjestely
PL356432A1 (en) Cooling element and method for manufacturing cooling elements
AP2002002626A0 (en) Method for manufacturing a cooling element and a cooling element
EP1058644A4 (en) DERIVATIVE
FI20001594A7 (fi) Täyttömenetelmä
GB0006524D0 (en) Film manufacturing method
GB9819783D0 (en) Manufacturing method
GB9919654D0 (en) Manufacturing method
GB9823086D0 (en) Film manufacturing method
PL357351A1 (en) Flat element and method for producing a flat element
SG73621A1 (en) Slider and method for manufacturing the same
GB2359742B (en) An element for a support structure and a support structure formed therefrom
GB9910350D0 (en) Manufacturing method
DE69916377D1 (de) Speicheranordnung und -verfahren
GB0014077D0 (en) Manufacturing method
TW496463U (en) Improved shading structure
GB9916954D0 (en) Manufacturing method